Kalvista Pharmaceuticals, Ltd.
Clinical trials sponsored by Kalvista Pharmaceuticals, Ltd., explained in plain language.
-
New pill shows promise for kids with rare swelling disorder
Disease control CompletedThis study tested an oral medicine called sebetralstat in 36 children aged 2 to 11 with hereditary angioedema (HAE) Types I or II, a condition causing sudden, painful swelling attacks. The main goal was to check safety and how the body processes the drug. Researchers also measure…
Phase: PHASE3 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated May 26, 2026 12:05 UTC
-
Real-World data on HAE attack treatment collected in completed study
Knowledge-focused CompletedThis study followed 88 people with hereditary angioedema (HAE) types I or II who already use icatibant for sudden attacks. Participants filled out diaries for 48 hours after each attack to report symptom changes and anxiety levels. The goal was to understand how well icatibant wo…
Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Knowledge-focused
Last updated May 18, 2026 12:13 UTC